ERBB2 and breast cancer: Gris–Oliver and colleagues suggested that 64% of HER2-negative BC xenografts with resistance to eribulin (microtubule inhibitors) show PIK3CA, PIK3R1, or AKT1 mutation, indicating that PI3K pathway activation may induce resistance or early adaptation to microtubule inhibitors (45).